Global Acute Myeloid Leukemia Market Growth (Status and Outlook) 2023-2029

Global Acute Myeloid Leukemia Market Growth (Status and Outlook) 2023-2029

Leukemia are a heterogeneous group of cancers affecting the bone marrow and White Blood Cells (WBC). Leukemia is characterized by the rapid increase of abnormal blood cells growth or blasts, resulting in a decrease in the numbers of healthy, normal fully modified blood cells, leading to the typical symptoms of bleeding, anemia, and high risk of infection. 

LPI (LP Information)' newest research report, the “Acute Myeloid Leukemia Industry Forecast” looks at past sales and reviews total world Acute Myeloid Leukemia sales in 2022, providing a comprehensive analysis by region and market sector of projected Acute Myeloid Leukemia sales for 2023 through 2029. With Acute Myeloid Leukemia sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Acute Myeloid Leukemia industry.

This Insight Report provides a comprehensive analysis of the global Acute Myeloid Leukemia landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Acute Myeloid Leukemia portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Acute Myeloid Leukemia market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Acute Myeloid Leukemia and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Acute Myeloid Leukemia.

The global Acute Myeloid Leukemia market size is projected to grow from US$ 1276.2 million in 2022 to US$ 3093.9 million in 2029; it is expected to grow at a CAGR of 13.5% from 2023 to 2029.

Primary drivers boosting the growth of acute myeloid leukemia (AML) therapeutics market are minimal but increased prevalence of acute myeloid leukemia (AML), increased drug approval rate for AML, classification of acute myeloid leukemia (AML) as an orphan disease. Over the forecast period, population of people over 65 year is anticipated to increase, which is another key driver for acute myeloid leukemia (AML) therapeutics market.

This report presents a comprehensive overview, market shares, and growth opportunities of Acute Myeloid Leukemia market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Chemotherapy
Radiation Therapy
Stem Cell Transplant
Targeted Therapy
Others

Segmentation by application
Hospital
Retails Drug Stores
Ambulatory Care Centers
Oncology Centers
Clinics

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Celgene Corporation
Cephalon
Clavis Pharma
Eisai
Genzyme Corporation
Sunesis Pharmaceuticals
Abbvie
Astellas Pharma
CTI Biopharma Corp

Please note: The report will take approximately 2 business days to prepare and deliver.